RMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

1.40B

+8.96%

2.714

+11.71%

1.41B

+9.09%

2.768

+16.79%

1.46B

+8.26%

2.876

+12.78%

Estimates Revision

The market is revising Upward the revenue expectations for ResMed Inc. (RMD) for FY2026, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by -9.14%.

Revenue Estimates for FY2026

Revise Upward

+0.02%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+877.79%

In Past 3 Month

Stock Price

Go Down

-9.14%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast RMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMD is 302.56 USD with a low forecast of 270.00 USD and a high forecast of 335.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

270.00

Averages

302.56

High

335.00

Current: 0.000

Low

270.00

Averages

302.56

High

335.00

Stifel

Jonathan Block

Hold

downgrade

$270 -> $260

2025-12-18

Reason

Stifel

Jonathan Block

Price Target

$270 -> $260

2025-12-18

downgrade

Hold

Reason

Stifel analyst Jonathan Block lowered the firm's price target on ResMed to $260 from $270 and keeps a Hold rating on the shares. The stock's recent pullback is "intriguing," but if FY27 revenue growth decelerates to a mid-single digit percentage, the current EPS multiple "might be appropriate in the near term," the analyst tells investors.

Baird

Outperform -> Neutral

downgrade

$300 -> $275

2025-12-16

Reason

Baird

Price Target

$300 -> $275

2025-12-16

downgrade

Outperform -> Neutral

Reason

Baird downgraded ResMed to Neutral from Outperform with a price target of $275, down from $300. The firm adjusted ratings and medical technology as part of its 2026 outlook. It cites "waning visibility" into ResMed's earnings and revenue along with increasing headline-risk around competitor expansion for the downgrade.

Baird

Outperform -> NULL

downgrade

$320 -> $300

2025-11-03

Reason

Baird

Price Target

$320 -> $300

2025-11-03

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on ResMed to $300 from $320 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q3 results.

Morgan Stanley

David Bailey

Overweight

maintain

$304 -> $305

2025-10-31

Reason

Morgan Stanley

David Bailey

Price Target

$304 -> $305

2025-10-31

maintain

Overweight

Reason

Morgan Stanley analyst David Bailey raised the firm's price target on ResMed to $305 from $304 and keeps an Overweight rating on the shares after the company delivered a "slightly better-than-expected" fiscal Q1 result, supported by "solid" operating leverage.

KeyBanc

Brett Fishbin

Overweight

maintain

$298 -> $299

2025-10-31

Reason

KeyBanc

Brett Fishbin

Price Target

$298 -> $299

2025-10-31

maintain

Overweight

Reason

KeyBanc analyst Brett Fishbin raised the firm's price target on ResMed to $299 from $298 and keeps an Overweight rating on the shares post Q1 on higher estimates. The firm viewed ResMed's Q1 2026 release as mostly positive given a modest revenue beat and sustained margin inflection. However, there were a few areas to nitpick, KeyBanc adds. More specifically, the firm notes Q1 revenue was slightly ahead of expectations, as outperformance in Devices was partially offset by Masks and Accessories and SAAS; KeyBanc was again encouraged by upside to gross margin, and it appears well on track to meet the 61%-63% guidance range for FY26; and it anticipates continued flexibility in capital allocation.

Mizuho

Outperform

NULL

downgrade

$310 -> $300

2025-10-31

Reason

Mizuho

Price Target

$310 -> $300

2025-10-31

downgrade

Outperform

NULL

Reason

Mizuho lowered the firm's price target on ResMed to $300 from $310 and keeps an Outperform rating on the shares following the fiscal Q1 report. The firm says GLP-1s are not presenting a headwind yet for ResMed while its US competition is stable.

Valuation Metrics

The current forward P/E ratio for Resmed Inc (RMD.N) is 21.84, compared to its 5-year average forward P/E of 29.26. For a more detailed relative valuation and DCF analysis to assess Resmed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

29.26

Current PE

21.84

Overvalued PE

38.65

Undervalued PE

19.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

21.98

Current EV/EBITDA

15.54

Overvalued EV/EBITDA

27.07

Undervalued EV/EBITDA

16.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.40

Current PS

6.26

Overvalued PS

8.97

Undervalued PS

5.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RMD News & Events

Events Timeline

No data

News

3.5

2025-12-31Businesswire

ResMed Inc (RMD) Releases 2025 Product Pipeline Analysis to Enhance Market Decision-Making

1.0

2025-12-18Globenewswire

Resmed CEO Mick Farrell to Present at 2026 J.P. Morgan Healthcare Conference

6.0

2025-12-18Benzinga

GE Vernova Expected to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday

People Also Watch

Frequently Asked Questions

What is Resmed Inc (RMD) stock price today?

The current price of RMD is 252.47 USD — it has increased 0.62 % in the last trading day.

What is Resmed Inc (RMD)'s business?

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

What is the price predicton of RMD Stock?

What is Resmed Inc (RMD)'s revenue for the last quarter?

Resmed Inc revenue for the last quarter amounts to 1.34B USD, increased 9.07 % YoY.

What is Resmed Inc (RMD)'s earnings per share (EPS) for the last quarter?

Resmed Inc. EPS for the last quarter amounts to 2.37 USD, increased 12.32 % YoY.

What changes have occurred in the market's expectations for Resmed Inc (RMD)'s fundamentals?

How many employees does Resmed Inc (RMD). have?

Resmed Inc (RMD) has 10600 emplpoyees as of January 10 2026.

What is Resmed Inc (RMD) market cap?

Today RMD has the market capitalization of 36.85B USD.